0001209191-23-013006.txt : 20230224
0001209191-23-013006.hdr.sgml : 20230224
20230224203520
ACCESSION NUMBER: 0001209191-23-013006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230222
FILED AS OF DATE: 20230224
DATE AS OF CHANGE: 20230224
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HANLY ANN M.
CENTRAL INDEX KEY: 0001854528
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39083
FILM NUMBER: 23669673
MAIL ADDRESS:
STREET 1: C/O VIR BIOTECHNOLOGY, INC.
STREET 2: 499 ILLINOIS STREET, SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vir Biotechnology, Inc.
CENTRAL INDEX KEY: 0001706431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 812730369
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-906-4324
MAIL ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-22
0
0001706431
Vir Biotechnology, Inc.
VIR
0001854528
HANLY ANN M.
C/O VIR BIOTECHNOLOGY, INC.
499 ILLINOIS STREET, SUITE 500
SAN FRANCISCO
CA
94158
0
1
0
0
Chief Technology Officer
Common Stock
2023-02-22
4
A
0
37500
0.00
A
119505
D
Common Stock
2023-02-23
4
S
0
2302
25.973
D
117203
D
Common Stock
11.52
I
See footnote
Stock Option (Right to Buy)
27.01
2023-02-22
4
A
0
55000
0.00
A
2033-02-21
Common Stock
55000
55000
D
Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
Includes 532 shares of common stock acquired by the reporting person on May 31, 2022 pursuant to an employee stock purchase program.
Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
The shares are beneficially owned by the reporting person's spouse, for the benefit of a minor child.
25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter.
/s/ Howard Horn, Attorney-in-Fact
2023-02-24